1231930-29-2 Usage
Uses
Used in Pharmaceutical Industry:
EthaniMidaMide, N-(4-broMo-2,6-difluorophenyl)-N'-(1-Methylethyl)is used as a sedative-hypnotic medication for its calming effect on the central nervous system. It is particularly effective in treating anxiety and insomnia, providing relief to patients suffering from these conditions.
Used in Anesthesia:
EthaniMidaMide, N-(4-broMo-2,6-difluorophenyl)-N'-(1-Methylethyl)is sometimes used in combination with other medications for anesthesia, particularly in surgical procedures. Its sedative and hypnotic properties contribute to a more comfortable and less stressful experience for patients undergoing surgery.
Used in Anticonvulsant Therapy:
As an anticonvulsant, EthaniMidaMide, N-(4-broMo-2,6-difluorophenyl)-N'-(1-Methylethyl)is used to control seizures and prevent convulsions in patients with epilepsy or other seizure disorders. Its ability to suppress abnormal electrical activity in the brain helps maintain a stable neurological state.
Used in Muscle Relaxation:
EthaniMidaMide, N-(4-broMo-2,6-difluorophenyl)-N'-(1-Methylethyl)is also used as a muscle relaxant, helping to alleviate muscle spasms and tension. This makes it useful in the treatment of various muscle-related conditions, such as muscle stiffness or spasticity.
Check Digit Verification of cas no
The CAS Registry Mumber 1231930-29-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,1,9,3 and 0 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1231930-29:
(9*1)+(8*2)+(7*3)+(6*1)+(5*9)+(4*3)+(3*0)+(2*2)+(1*9)=122
122 % 10 = 2
So 1231930-29-2 is a valid CAS Registry Number.
1231930-29-2Relevant academic research and scientific papers
COMBINATION THERAPY FOR CANCER
-
Page/Page column 21, (2015/09/28)
The present invention provides preparation of medicaments for use in treating and methods of treating non-small cell lung cancer in a patient comprising: [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H- benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, or a pharmaceutically acceptable salt thereof, in combination, as further described herein, with an anti-VEGFR2 antibody, preferably, ramucirumab.
PROTEIN KINASE INHIBITORS
-
Page/Page column 10, (2010/07/04)
The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.
